Skip to main content
Lunai Bioworks Inc. logo

Lunai Bioworks Inc. — Investor Relations & Filings

Ticker · RENB ISIN · US29350E1047 US Professional, scientific and technical activities
Open in API
Filings indexed 580 across all filing types
Latest filing 2014-08-08 Capital/Financing Update
Country US United States of America
Listing US RENB

About Lunai Bioworks Inc.

https://www.lunaibio.com

Lunai Bioworks Inc. is a pre-clinical stage biotechnology company that utilizes artificial intelligence for drug discovery and biodefense. The company focuses on pioneering safe and responsible generative biology to develop new therapies. By harnessing phenomics and AI, it aims to decode disease signals and translate them into treatments. Its proprietary Transformer Platform is designed to accelerate drug discovery processes. Lunai Bioworks develops medicines, diagnostics, and biodefense products, with a pipeline that includes programs for neurodegenerative conditions like Alzheimer's disease.

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2014
Capital/Financing Update Classification · 95% confidence The document is a letter from a placement agent requesting acceleration of the effective date of a Registration Statement on Form S-1, which is related to a proposed public offering. It references securities laws and regulatory compliance but does not contain financial statements, earnings data, or detailed financial analysis. The document is short (2984 characters) and serves as a regulatory communication related to a capital raising process. It is not a full report but an update or request related to financing activities. Therefore, it fits best under Capital/Financing Update (CAP).
2014-08-08 English
Regulatory Filings 2014
Regulatory Filings Classification · 95% confidence The document is a letter responding to comments from the SEC staff regarding a Registration Statement on Form S-1 and its amendments. It discusses corrections and revisions made to the Registration Statement, including Management's Discussion and Analysis, business information, and related party transactions. The letter is not the Registration Statement itself but a correspondence addressing SEC comments and amendments. The document length is 4065 characters, which is relatively short and primarily a regulatory correspondence. Therefore, it fits best under Regulatory Filings (RNS), as it is a regulatory communication and does not contain the full report or financial statements itself.
2014-08-08 English
AMENDMENT TO REGISTRATION STATEMENT
Capital/Financing Update Classification · 95% confidence The document is a Form S-1/A, which is an amendment to a registration statement filed with the SEC under the Securities Act of 1933. It is related to an initial public offering (IPO) of common stock by DanDrit Biotech USA, Inc. The text includes detailed information about the offering, use of proceeds, risk factors, management, and other disclosures typical of a registration statement prospectus. This type of filing is a capital raising document and is not an annual report, earnings release, or other financial report. It is specifically a registration statement amendment related to capital raising activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or notice, so it is not a Report Publication Announcement or Regulatory Filing. Confidence is high due to the clear identification of the form and content.
2014-08-08 English
Regulatory Filings 2014
Regulatory Filings
2014-08-06 English
Regulatory Filings 2014
Regulatory Filings Classification · 95% confidence The document is a detailed response letter to the SEC regarding comments on a Registration Statement on Form S-1 and its amendments. It discusses clinical trials, management's discussion and analysis, and clarifications about the company's role in clinical trials. The document references the Registration Statement on Form S-1 multiple times and addresses SEC staff comments on disclosures related to the company's business and clinical trials. The content is regulatory in nature, responding to SEC comments on a registration statement for an offering, which is a capital markets filing. The document does not contain financial statements or earnings data, nor is it a full annual or quarterly report. It is not a proxy, governance, or remuneration document. It is not a transcript or legal proceeding update. The document is a regulatory filing responding to SEC comments on a registration statement, which fits best under Regulatory Filings (RNS). The length and detail confirm it is not a brief announcement or report publication announcement. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2014-07-25 English
AMENDMENT TO REGISTRATION STATEMENT
Capital/Financing Update Classification · 95% confidence The document is a Form S-1/A, which is an amendment to a registration statement filed with the SEC under the Securities Act of 1933. It is related to an initial public offering (IPO) of common stock by DanDrit Biotech USA, Inc. The text includes detailed information about the offering, use of proceeds, risk factors, management, and other disclosures typical of a registration statement prospectus. This type of filing is related to capital raising and financing activities rather than a financial report, earnings release, or management discussion. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is not merely an announcement or certification but the actual registration statement amendment. Hence, the classification is CAP with high confidence.
2014-07-25 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.